液體切片市場機會、成長促進因素、產業趨勢分析及預測（2025-2034年）

2024 年全球液體活體組織切片市場價值為 48 億美元，預計到 2034 年將以 15.8% 的複合年成長率成長至 207 億美元。

癌症診斷技術的不斷進步、非侵入性檢測方法的普及、癌症發病率的上升以及人們對早期檢測意識的增強，共同推動了液體活體組織切片的發展。隨著全球醫療系統增加基礎設施投入並擴大篩檢覆蓋範圍，可擴展、精準的工具（例如液體活體組織切片）的需求持續成長。對早期識別和精準醫療的日益重視，為液體活體組織切片在臨床應用中的推廣提供了沃土。此檢測方法可以直接從體液中檢測和分析腫瘤來源的生物標記物，例如遊離DNA、循環腫瘤細胞和細胞外囊泡，為傳統的組織活體組織切片提供了更安全、更快捷的替代方案。液體活體組織切片的應用範圍涵蓋癌症診斷、突變追蹤和治療監測，正逐漸成為一種變革性的解決方案，尤其適用於高風險和弱勢患者群體。它能夠在最大限度降低手術風險的同時提供可操作的見解，因此在研究機構、醫院和診斷實驗室中得到了更廣泛的應用。

2024年，循環腫瘤細胞（CTC）市場規模預計將達19億美元。這些細胞從原發腫瘤脫落並通過血液循環進入體內，對於即時揭示腫瘤動態變化具有重要價值。從成像平台到微流控技術，用於分離和分析CTC的技術正幫助臨床醫生了解腫瘤的演化、抗藥性機制和基因譜。 CTC的非侵入性和在即時監測中的作用，使其成為液體活體組織切片生態系統中日益重要的組成部分，並拓展了其臨床應用價值。

預計到2024年，癌症應用領域將佔據85.8%的市場。全球癌症負擔的持續加重，不斷提升了對更快、更微創、更精準的診斷方法的需求。液體活體組織切片有望更早發現惡性腫瘤，更有效地制定個人化治療方案，並在無需手術干預的情況下監測治療反應。其在腫瘤學領域的日益普及，源自於對更個人化、以患者為中心的治療策略的需求，這些策略能夠縮短診斷時間並改善治療效果。

2024年北美液體切片市場規模達20億美元，預計2034年將達84億美元。該地區的領先地位源於其強大的生物技術研究生態系統、政府在腫瘤領域的大量投資以及對先進診斷方案日益成長的需求。臨床和研究領域的高普及率，以及持續的產品創新和核准，都鞏固了該地區的市場地位。患者和醫療服務提供者對液體活體組織切片的認知度不斷提高，以及公共和私人資金支持的強勁研發管線，也為該地區的成長注入了新的動力。

推動全球液體切片市場發展的關鍵企業包括Myriad Genetics、BIOCEPT、Thermo Fisher Scientific、Guardant Health、F. Hoffmann La Roche、Menarini Silicon Biosystems、Lucene Health、Oncimmune、Illumina、EPIGENOMICS、Freenome Holdings、QIAGEN、Bio-Rad Labories、Healthx、Healthx、Healthn、BioxAn、THealthEN、Bio-Rad Labories、Healthx、BioxAngle、Freenome Holdings、QIAGEN、Bio-Rad Labories、Healthx、BioxAngle、Freenome Holdings、QIAGEN、Bio-Rad Labories、Healthx、BioxAngle、Freenome Holdings、QIAGEN、Bio-Rad Labories、Healthx、BioxAngle、Freenome Holdings、QIAGEN、Bio-Rad Labories、Healthx、BioxAngle、Freenome Holdings、QIAGEN、Bio-Rad Labories、Healthx、BioxAngle、Freenome Holdings、QIAGEN、Bio-Rad Labories、Healthx、BioxAngle、Freenome Holdings、QIAGEN、Bio-Rad Labor）。這些企業正採取多角化策略來鞏固和提升其市場地位。其主要重點在於拓展早期癌症檢測和監測解決方案的研發管線。與科研機構和醫院的策略合作有助於加速臨床驗證，並擴大新興技術的應用範圍。許多公司正在開發由人工智慧驅動的平台，以提高生物標記檢測的準確性並簡化結果解讀。

目錄

第1章：方法論與範圍

第2章：執行概要

第3章：行業洞察

• 產業生態系分析
• 產業影響因素
  • 成長促進因素
    • 癌症診斷技術的不斷進步
    • 人們越來越傾向於非侵入性疾病診斷
    • 全球癌症發生率不斷上升
    • 人們越來越關注疾病的早期診斷
  • 產業陷阱與挑戰
    • 嚴格的監管框架
    • 缺乏熟練的專業人員
  • 市場機遇
    • 擴大多癌種早期檢測（MCED）測試
• 成長潛力分析
• 監管環境
• 技術進步
  • 當前技術趨勢
  • 新興技術
• 供應鏈分析
• 報銷方案
• 2024年定價分析
• 未來市場趨勢
• 差距分析
• 波特的分析
• PESTEL 分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 關鍵進展
  • 併購
  • 夥伴關係與合作
  • 新產品發布
  • 擴張計劃

第5章：市場估算與預測：依生物標記分類，2021-2034年

• 主要趨勢
• 循環腫瘤細胞（CTC）
• 循環腫瘤DNA
• 無細胞DNA
• 細胞外囊泡
• 其他生物標記

第6章：市場估算與預測：依產品分類，2021-2034年

• 主要趨勢
• 消耗品
  • 試劑盒和試劑
  • 檢測和檢測組
• 儀器
• 服務

第7章：市場估計與預測：依疾病適應症分類，2021-2034年

• 主要趨勢
• 癌症
  • 肺癌
  • 乳癌
  • 大腸直腸癌
  • 攝護腺癌
  • 其他癌症
• 非癌症
  • 非侵入性產前檢測
  • 器官移植
  • 傳染病檢測

第8章：市場估算與預測：依臨床應用用途分類，2021-2034年

• 主要趨勢
• 治療監測
• 預後和復發監測
• 治療選擇
• 診斷和篩檢

第9章：市場估計與預測：依技術分類，2021-2034年

• 主要趨勢
• 多基因平行分析（NGS）
• 單基因分析（PCR微陣列）

第10章：市場估計與預測：依最終用途分類，2021-2034年

• 主要趨勢
• 醫院
• 研究實驗室
• 臨床實驗室
• 其他最終用途

第11章：市場估計與預測：按地區分類，2021-2034年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 沙烏地阿拉伯
  • 南非
  • 阿拉伯聯合大公國

第12章：公司簡介

• Angle
• BIOCEPT
• Bio-Rad Laboratories
• EPIGENOMICS
• F. Hoffmann La Roche
• Freenome Holdings
• Guardant Health
• Illumina
• Lucene Health
• MDxHealth
• Menarini Silicon Biosystems
• Myriad Genetics
• Oncimmune
• QIAGEN
• Thermo Fisher Scientific

The Global Liquid Biopsy Market was valued at USD 4.8 billion in 2024 and is estimated to grow at a CAGR of 15.8% to reach USD 20.7 billion by 2034.

The growth is being fueled by rising advancements in cancer diagnostics, a shift toward non-invasive methods, increasing cancer prevalence, and greater awareness around early detection. As healthcare systems globally invest in infrastructure and expand screening access, demand for scalable, accurate tools like liquid biopsy continues to accelerate. The growing focus on early-stage identification and precision medicine is creating fertile ground for the integration of liquid biopsy into clinical settings. The test allows the detection and analysis of tumor-derived biomarkers such as cell-free DNA, circulating tumor cells, and extracellular vesicles directly from bodily fluids, offering a safer and faster alternative to traditional tissue biopsies. With applications spanning cancer diagnosis, mutation tracking, and treatment monitoring, liquid biopsy is proving to be a transformative solution, especially for high-risk and vulnerable patient populations. Its ability to minimize procedural risks while delivering actionable insights supports broader adoption across research institutions, hospitals, and diagnostic labs.

In 2024, the circulating tumor cells segment generated USD 1.9 billion. These cells, which detach from primary tumors and travel through the bloodstream, are valuable in revealing tumor dynamics in real time. Technologies used to isolate and analyze CTCs, ranging from imaging platforms to microfluidics, are enabling clinicians to understand tumor evolution, resistance mechanisms, and genetic profiles. Their non-invasive nature and role in real-time monitoring make CTCs an increasingly important component of the liquid biopsy ecosystem, broadening its clinical relevance.

The cancer application segment held an 85.8% share in 2024. The steadily rising global burden of cancer continues to elevate the demand for faster, less invasive, and highly precise diagnostic methods. Liquid biopsy offers the potential to detect malignancies earlier, tailor therapies more effectively, and monitor responses without requiring surgical interventions. Its growing adoption in oncology is being driven by the need for more personalized, patient-centric treatment strategies that reduce time-to-diagnosis and improve care outcomes.

North America Liquid Biopsy Market generated USD 2 billion in 2024 and is expected to reach USD 8.4 billion by 2034. The region's leadership stems from its strong biotechnology research ecosystem, significant government investments in oncology, and rising demand for advanced diagnostic options. High adoption rates across clinical and research environments, along with regular product innovation and approvals, are helping solidify the region's position. Rising awareness among patients and providers, along with robust R&D pipelines supported by public and private funding, is adding momentum to regional growth.

Key players shaping the Global Liquid Biopsy Market include Myriad Genetics, BIOCEPT, Thermo Fisher Scientific, Guardant Health, F. Hoffmann La Roche, Menarini Silicon Biosystems, Lucene Health, Oncimmune, Illumina, EPIGENOMICS, Freenome Holdings, QIAGEN, Bio-Rad Laboratories, MDxHealth, and Angle. Companies in the Liquid Biopsy Market are deploying multi-faceted strategies to build and protect their market positions. A primary focus lies in expanding R&D pipelines for early-stage cancer detection and monitoring solutions. Strategic collaborations with research institutes and hospitals help accelerate clinical validation and widen access to emerging technologies. Many firms are developing AI-driven platforms to improve the accuracy of biomarker detection and streamline interpretation.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Biomarkers trends
  • 2.2.3 Product trends
  • 2.2.4 Disease indication trends
  • 2.2.5 Clinical application trends
  • 2.2.6 Technology trends
  • 2.2.7 End use trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Continuous technological advancements in cancer diagnostics
    • 3.2.1.2 Increasing preference for non-invasive disease diagnosis
    • 3.2.1.3 Growing prevalence of cancer worldwide
    • 3.2.1.4 Rising awareness regarding early disease diagnosis
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulatory framework
    • 3.2.2.2 Lack of skilled professionals
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expansion of multi-cancer early detection (MCED) tests
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Technological advancements
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Supply chain analysis
• 3.7 Reimbursement scenario
• 3.8 Pricing analysis, 2024
• 3.9 Future market trends
• 3.10 Gap analysis
• 3.11 Porter's analysis
• 3.12 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers and acquisitions
  • 4.6.2 Partnerships and collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Biomarkers, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Circulating tumor cells (CTC)
• 5.3 Circulating tumor DNA
• 5.4 Cell-free DNA
• 5.5 Extracellular vesicles
• 5.6 Other biomarkers

Chapter 6 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Consumables
  • 6.2.1 Kits and reagents
  • 6.2.2 Assay and panels
• 6.3 Instruments
• 6.4 Services

Chapter 7 Market Estimates and Forecast, By Disease Indication, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Cancer
  • 7.2.1 Lung cancer
  • 7.2.2 Breast cancer
  • 7.2.3 Colorectal cancer
  • 7.2.4 Prostate cancer
  • 7.2.5 Other cancers
• 7.3 Non-cancer
  • 7.3.1 Non-invasive prenatal testing
  • 7.3.2 Organ transplantation
  • 7.3.3 Infectious disease testing

Chapter 8 Market Estimates and Forecast, By Clinical Application Use, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Treatment monitoring
• 8.3 Prognosis and recurrence monitoring
• 8.4 Treatment selection
• 8.5 Diagnosis and screening

Chapter 9 Market Estimates and Forecast, By Technology, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Multi-gene parallel analysis (NGS)
• 9.3 Single gene analysis (PCR Microarrays)

Chapter 10 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 10.1 Key trends
• 10.2 Hospitals
• 10.3 Research Laboratories
• 10.4 Clinical Laboratories
• 10.5 Other end use

Chapter 11 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 11.1 Key trends
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 France
  • 11.3.4 Spain
  • 11.3.5 Italy
  • 11.3.6 Netherlands
• 11.4 Asia Pacific
  • 11.4.1 China
  • 11.4.2 India
  • 11.4.3 Japan
  • 11.4.4 Australia
  • 11.4.5 South Korea
• 11.5 Latin America
  • 11.5.1 Brazil
  • 11.5.2 Mexico
  • 11.5.3 Argentina
• 11.6 Middle East and Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 South Africa
  • 11.6.3 UAE

Chapter 12 Company Profiles

• 12.1 Angle
• 12.2 BIOCEPT
• 12.3 Bio-Rad Laboratories
• 12.4 EPIGENOMICS
• 12.5 F. Hoffmann La Roche
• 12.6 Freenome Holdings
• 12.7 Guardant Health
• 12.8 Illumina
• 12.9 Lucene Health
• 12.10 MDxHealth
• 12.11 Menarini Silicon Biosystems
• 12.12 Myriad Genetics
• 12.13 Oncimmune
• 12.14 QIAGEN
• 12.15 Thermo Fisher Scientific